News
TGTX
14.31
+3.55%
0.49
TG Therapeutics wins VA contract for Briumvi
TG Therapeutics wins VA contract for Briumvi. Multiple sclerosis therapy listed as preferred therapy for the central nervous system disorder. The one-year contract takes effect in June 2024. European drugmakers Novartis and Roche also market antibodies for MS. The company estimates the contract value at $186.8M.
Seeking Alpha · 9h ago
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)
TipRanks · 13h ago
TG THERAPEUTICS ANNOUNCES ADDITIONAL DATA PRESENTATIONS FOR BRIUMVI® (UBLITUXIMAB-XIIY) IN MULTIPLE SCLEROSIS AT THE AMERICAN ACADEMY OF NEUROLOGY 2024 ANNUAL MEETING
Reuters · 15h ago
TG THERAPEUTICS INC - TOTAL AWARD AMOUNT OF CONTRACT HAS A POTENTIAL VALUE OF $186.8 MLN
Reuters · 16h ago
TG THERAPEUTICS AWARDED NATIONAL CONTRACT BY THE DEPARTMENT OF VETERANS AFFAIRS FOR BRIUMVI AS THE PREFERRED ANTI-CD20 FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS
Reuters · 16h ago
TG Therapeutics Inc Awarded $186,776,520 Contract From Department Of Veterans Affairs, NAC Pharmaceuticals For Pharmaceutical Preparation Manufacturing 6505--Anti CD20 Antibodies
Benzinga · 1d ago
TG Therapeutics: The Cloud Over Briumvi
TG Therapeutics shares are down 60% from their 52-week high after rival MS therapy Ocrevus achieved non-inferiority as a subcutaneously injected therapy. Initial sales of the company's anti-CD20 MS treatment Briumvi were solid, generating $92 million in FY23. The company is developing a version of the drug to compete with Roche's SC OCrevus, expected to be approved in 2024.
Seeking Alpha · 1d ago
TG Therapeutics Becomes Oversold (TGTX)
NASDAQ · 3d ago
Weekly Report: what happened at TGTX last week (0408-0412)?
Weekly Report · 3d ago
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
TG Therapeutics, Inc. Presented data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The data will be presented at the 2024 American Academy of Neurology annual meeting in Denver, Colorado.
Barchart · 3d ago
TG Therapeutics: BRIUMVI Development Could Lead To Great Results
TG Therapeutics launched its multiple sclerosis drug BRIUMVI in January 2023. The company has strong barriers to entry and patent protection for the drug. Hedge funds have started reinvesting in the company, indicating confidence in its future prospects. The share price seems expensive today, but the company has potential growth in 2024 and 2025.
Seeking Alpha · 6d ago
Weekly Report: what happened at TGTX last week (0401-0405)?
Weekly Report · 04/08 11:58
Benjamin Graham Detailed Fundamental Analysis - TGTX
NASDAQ · 04/01 16:05
Weekly Report: what happened at TGTX last week (0325-0329)?
Weekly Report · 04/01 11:55
Weekly Report: what happened at TGTX last week (0318-0322)?
Weekly Report · 03/25 11:58
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
NASDAQ · 03/25 10:20
Weekly Report: what happened at TGTX last week (0311-0315)?
Weekly Report · 03/18 11:56
(TGTX) - Analyzing TG Therapeutics's Short Interest
TG Therapeutics's short percent of float has fallen 5.17% since its last report. The company has 29.12 million shares sold short. Short interest is the number of shares that have been sold short but have not yet been covered or closed out. It can act as an indicator of market sentiment towards a stock.
Benzinga · 03/13 19:00
Weekly Report: what happened at TGTX last week (0304-0308)?
Weekly Report · 03/11 11:51
Rare Stock Picks In February 2024 - From 32 Discerning Analysts
Rare Stock Picks in February 2024 - From 32 Discerning Analysts have no other Buy/Strong Buy recommendations in the past 3 months. The new investment ideas were made by analysts who have no previous buy recommendations. The February 2024 investment picks include HP, AMD, Gilead Sciences, Teva, and Molina Healthcare.
Seeking Alpha · 03/05 15:00
More
Webull provides a variety of real-time TGTX stock news. You can receive the latest news about Tg Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.